Background: we depict the experience with the use of thrombolysis for acute ischemic stroke in a tertiary center in South America.Objective: to describe the main outcomes in our population of patients aged less and older than 80 years treated with recombinant tissue plasminogen activator.Materials and Methods: retrospective observational study.We described the main variables and the difference in outcome accounting for age.Results: 70 patients were included.51.4% of the patients were women, 22.8% were older than 80 years.The average window time was 70 minutes and the average door-to-needle time was 90 minutes.Hypertension, dyslipidemia and previous stroke were the most common risk factors.Favorable outcome Modified Rankin Scale ≤2 was present in 25% of the patients older than 80 years and 53.7% in the population younger than 80 years (p=0.009).Mortality was present in 31.2% of the patients older than 80 years and in 5.5% of the patients younger than 80 years (p=0.005).Symptomatic intra-cerebral hemorrhage was found in 6.25% of the patients older than 80 years (p=0.65),compared to 3.7% in the younger than 80 years.Conclusions: we found that intravenous thrombolysis still had benefit in people older than 80 years.Significant differences in symptomatic intra-cerebral hemorrhage were not found, however, a greater mortality in patients older than 80 years was.These findings of our experience of recombinant tissue plasminogen activator use in real life are consistent with other latinamerican publications.MÉD.UIS.